Scopus BioPharma Inc. (SCPS)

USD 0.0

(0.0%)

Market Cap (In USD)

12.62 Thousand

Revenue (In USD)

-

Net Income (In USD)

-11.6 Million

Avg. Volume

504.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-4-0.0637
PE
-
EPS
-
Beta Value
38.663
ISIN
US8091711015
CUSIP
809171101
CIK
1772028
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alan D. Horsager Ph.D.
Employee Count
-
Website
https://scopusbiopharma.com
Ipo Date
2020-12-16
Details
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.